Literature DB >> 8562957

The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion.

R L Redner1, E A Rush, S Faas, W A Rudert, S J Corey.   

Abstract

We have studied an acute promyelocytic leukemia (APL) patient with a variant t(5;17)(q32;q12). This translocation fuses the gene for the nucleolar phosphoprotein nucleophosmin (NPM) to the retinoic acid receptor alpha (RARA). Two alternatively spliced transcripts are expressed, which differ in 129 bases immediately upstream of the RARA sequence. The NPM sequences contained in the shorter NPM-RAR cDNA are identical to the NPM sequences contained in the NPM-ALK fusion gene expressed in t(2;5) lymphomas. The RARA sequences are the same as the RARA sequences found in the PML-RAR and PLZF-RAR fusion seen in t(15;17) and t(11;17) APL, respectively. Both NPM-RAR transcripts fuse NPM and RARA sequence in the same reading frame, to generate translation products of 57 kD and 62 kD. Both NPM-RAR proteins are expressed in the patient's leukemic cells, along with wild-type RARA derived from the uninvolved allele. In transcriptional assays using a retinoic acid response element reporter construct, both NPM-RAR fusion proteins act as retinoic acid-dependent transcriptional activators. This case defines a third class of APL rearrangements, all of which generate fusion proteins of RARA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8562957

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  83 in total

1.  The CRM1 nuclear export protein in normal development and disease.

Authors:  Kevin T Nguyen; Michael P Holloway; Rachel A Altura
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

2.  SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia.

Authors:  S H Hong; G David; C W Wong; A Dejean; M L Privalsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

3.  The leukemic oncoprotein NPM1-RARA inhibits TP53 activity.

Authors:  Erin M Swaney; Anuja Chattopadhyay; Irina Abecassis; Elizabeth A Rush; Robert L Redner
Journal:  Leuk Lymphoma       Date:  2016-01-12

Review 4.  Nucleophosmin and human cancer.

Authors:  Mi Jung Lim; Xin Wei Wang
Journal:  Cancer Detect Prev       Date:  2006-11-17

Review 5.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

6.  Role of arsenic trioxide in acute promyelocytic leukemia.

Authors:  Harry J Iland; John F Seymour
Journal:  Curr Treat Options Oncol       Date:  2013-06

Review 7.  New insights into the genetics of neuroblastoma.

Authors:  Srishma Sridhar; Batool Al-Moallem; Hawra Kamal; Marta Terrile; Raymond L Stallings
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

8.  The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis.

Authors:  R Shaknovich; P L Yeyati; S Ivins; A Melnick; C Lempert; S Waxman; A Zelent; J D Licht
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

9.  Successful all-trans retinoic acid treatment of acute promyelocytic leukemia in a patient with NPM/RAR fusion.

Authors:  Kiyoshi Okazuka; Masayoshi Masuko; Yoshinobu Seki; Hitomi Hama; Noriyuki Honma; Tatsuo Furukawa; Ken Toba; Kenji Kishi; Yoshifusa Aizawa
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

10.  A novel gene, ANKRD28 on 3p25, is fused with NUP98 on 11p15 in a cryptic 3-way translocation of t(3;5;11)(p25;q35;p15) in an adult patient with myelodysplastic syndrome/acute myelogenous leukemia.

Authors:  Maho Ishikawa; Fumiharu Yagasaki; Daisuke Okamura; Tomoya Maeda; Yuichi Sugahara; Itsuro Jinnai; Masami Bessho
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.